Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter. Limits and monitoring Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 43, posted Oct 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter. Limits and monitoring Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 18, posted Aug 07, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal dysfunction reduces methotrexate elimination. Monitor closely for toxicity and reduce the dose or discontinue when indicated. Limits and monitoring Verify the once-weekly subcutaneous autoinjector, prescribed strength and indication. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 15, posted Feb 03, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal dysfunction reduces methotrexate elimination. Monitor closely for toxicity and reduce the dose or discontinue when indicated. Limits and monitoring Verify the once-weekly subcutaneous autoinjector, prescribed strength and indication. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 10, posted Dec 18, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Use metolazone cautiously in severe kidney disease. Discontinue if azotemia and oliguria worsen during treatment. Limits and monitoring Monitor fluid balance, potassium and other electrolytes as diuresis proceeds. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 3, posted Aug 08, 2016 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Avoid routine mitotane use in severe renal impairment. In mild or moderate impairment, monitor mitotane concentrations more frequently. Limits and monitoring Titrate against measured concentrations and clinical toxicity. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 18, posted Aug 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 20 mL/min or lower, a single-dose study found little change in parent modafinil disposition but about ninefold higher exposure to inactive modafinil acid. Limits and monitoring This study did not establish a dialysis schedule or a numeric dose reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Dec 10, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The montelukast label specifies no renal dose change. Limits and monitoring Choose the age- and indication-specific formulation and review the neuropsychiatric boxed warning. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 5, posted Jun 25, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding In kidney transplant recipients with severe chronic graft impairment and GFR below 25 mL/min/1.73 m2, avoid doses above 1 g twice daily. Limits and monitoring This instruction concerns chronic graft impairment after kidney transplantation. Verify the recipient population and formulation. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 51, posted Aug 10, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Avoid the product in severe renal impairment with CrCl below 30 mL/min or in ESRD. Mild or moderate impairment requires no dose change. Limits and monitoring Verify formulation. Oral netupitant and IV fosnetupitant are different presentations. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 19, posted Jun 25, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding At eGFR of at least 15 mL/min/1.73 m2, kidney function had no clinically important effect on nivolumab clearance. Limits and monitoring This baseline pharmacokinetic finding is separate from evaluation of immune-mediated nephritis. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 68, posted Aug 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding At eGFR 30-89 mL/min/1.73 m2, mild or moderate impairment had no clinically important influence on clearance of nivolumab and relatlimab. Limits and monitoring Review immune-mediated renal toxicity separately. The analysis gives no dialysis schedule. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 3, posted Jun 22, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
